Abstract library

9 results for "Grana".
#745 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) for Patients with Neuroendocrine Tumors (NETs) with Metastatic Abdominal Localizations.
Introduction: There are only few case reports about surgery in patients affected by gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously underwent peptide receptor radionuclide therapy (PRRT).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: MD Emilio Bertani
#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
Authors: Bertani E, Chiappa A, Fazio N, Grana C, ...
#949 An Analysis of Toxicity after Peptide Receptor Radionuclide Therapy (PRRT) in 807 Patients: Determination of the Limited Predictive Role of Clinical Factors
Introduction: PRRT with 90Y-octreotide (Y) and 177Lu-octreotate (Lu) is well-tolerated.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Lisa Bodei
Authors: Bodei L, Kidd M, Grana C, Severi S, ...
Keywords: NET, PRRT, risk, toxicity
#1120 Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET
Introduction: Oxaliplatine plus fluoropirimidine and capecitabine treatment alone are considered investigational treatments in well-differentiated (WD) NET
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
#1336 Resection of the Primary Tumor Prior to Peptide Receptor Radionuclide Therapy Improves Treatment Response and Progression-free Survival in Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases
Introduction: A low burden of disease represents an independent favorable prognostic factor of response to peptide receptor radionuclide therapy (PRRT) in patients affected by gastro-entero-pancreatic neuroendocrine tumors. However it is not clear whether this is due to a lower diffusion of the disease or thanks to debulking surgery
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Bodei L, ...
#1348 Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival?
Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Dr Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Chiappa A, ...
#1863 Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-Matched Analysis
Introduction: Neoadjuvant Peptide receptor radionuclide therapy (NPRRT) can be an option for advanced pancreatic neuroendocrine neoplasms (PNEN) before surgery. Is not clear if NPRRT increases postoperative morbidity
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Francesca Muffatti
#2072 Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study
Introduction: Gastroenteropancreatic (GEP) grade 3 neuroendocrine neoplasms (NEN G3) are rare, highly malignant neoplasms with poor prognosis and limited therapeutic options. Median survival following chemotherapy is only 10-12 months.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD, PhD Dorthe Skovgaard
#2706 A New Possibility in SI-NET Surgery by Using a New β- Probe and 90Y-DOTATOC: A Pilot Study
Introduction: In neuroendocrine tumor (NET), complete surgery could better the prognosis of this disease: radioguided surgery (RGS) with beta-radioisotopes, as 90Y, is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons.
Conference: 17th Annual ENETS Conference (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Chiara Maria Grana
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team